Led · Seed · Nov 2021

Gelatex develops nanofibrous 3D scaffolding intended for use in growing cell-cultured meat. The company has created a solution it says can scale and enhance production of those scaffolds. Gelatex plans to use recently raised funds to advance its development efforts. Leadership is headed by Märt-Erik Martens and Mari-Ann Meigo-Fonseca. The startup is based in Tallinn, Estonia. Financially, Gelatex completed a seed financing round described in the article.

Participated · Equity · Nov 2021

Sigrid Therapeutics develops clinically validated, non-systemic solutions for blood-sugar control and weight management based on its silica-particle SiPore® platform, which operates mechanically in the gut without entering systemic circulation. Its leading product, Glucose Stabiliser, is sold direct-to-consumer and through a growing U.S. physician network, achieving more than 3× revenue growth over the past year, evidencing strong product-market fit and repeat usage. The company is pursuing CE-mark authorization for an over-the-counter medical device targeting adults with excess weight and elevated blood sugar, and is also extending SiPore® into oral care, veterinary health, and food technology via prospective licensing partnerships. Founded on more than 15 years of research, Sigrid positions itself as a scalable platform business that can power multiple consumer-health categories. The fresh capital will accelerate U.S. expansion and regulatory efforts while supporting new vertical development. To date, Sigrid has raised approximately USD 27 million in total funding.